Futures contract

Grupo Supervielle Reports 2Q22 Results

Retrieved on: 
Mercredi, août 17, 2022
Finance, Banking, Professional Services, Other Professional Services, Fintech, NIM, SME, Income, Risk-weighted asset, CEO, NYSE, Growth, Share repurchase, Sale, Futures contract, Capital requirement, Asset, Environment, Government, Bank, LLP, Yoy, Company, Acquisition, NPL, Private sector, IFRS, Coverage, Loss, Common equity, BYMA, Quarter, CB Bank, Central bank, Efficiency, Music, Jules Supervielle, IOL

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three and six-months period ended June 30, 2022.

Key Points: 
  • Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three and six-months period ended June 30, 2022.
  • Starting 1Q20, the Company began reporting results applying Hyperinflation Accounting, in accordance with IFRS rule IAS 29 (IAS 29) as established by the Central Bank.
  • Excluding non-recurring severance charges, Supervielle would have delivered net loss of AR$1.2 billion in 2Q22, with adjusted ROAE in real terms at approximately negative 6.8%, compared to 2.9% in previous quarter.
  • 2Q22 Tier 1 Capital Ratio evolution reflects the growth of loan portfolio above inflation and impact of net results.

OXFORD BANK CORPORATION ANNOUNCES SECOND QUARTER AND SIX-MONTH 2022 OPERATING RESULTS

Retrieved on: 
Mercredi, juillet 27, 2022
Acquisition, Fed, FYE, FSW, Corporation, Asset, Treasury, CEO, Release, Private Securities Litigation Reform Act, Risk, Phrase, Bank, Income, Multimedia, OTC Bulletin Board, Company, Futures contract, PPP, Growth, Tier 1 capital, Cryptocurrency

OXFORD, Mich., July 27, 2022 /PRNewswire/ -- Oxford Bank Corporation ("the Company") (OTC Bulletin Board: OXBC), the holding company for Oxford Bank ("the Bank"), today announced operating results for the second quarter ended June 30, 2022.

Key Points: 
  • OXFORD, Mich., July 27, 2022 /PRNewswire/ -- Oxford Bank Corporation ("the Company") (OTC Bulletin Board: OXBC), the holding company for Oxford Bank ("the Bank"), today announced operating results for the second quarter ended June 30, 2022.
  • Second quarter 2022 earnings also increased, as expected, compared to first quarter net income of $1.059 million, or $.46 per weighted average share.
  • Oxford Bank is a subsidiary of Oxford Bank Corporation, a registered holding company.
  • In addition, Oxford Bank has business banking centers in Ann Arbor, Flint, Oxford, and Wixom, MI.

TD Ameritrade Makes Further Enhancements to thinkorswim®

Retrieved on: 
Jeudi, juillet 14, 2022
Personal Finance, Finance, Banking, Professional Services, Fintech, Online, TD Ameritrade, TD, Integrated development environment, Education, News, Investment, Trade Union Educational League, SIPC, Customer service, Profit & Loss, Research, Futures contract, Charles Schwab, Toronto-Dominion Bank, Customer support, Fee, Charles Schwab Corporation, Mobile, Thinkorswim, Usability, Beginners, Day, FINRA, Options strategy, IDE, Comparison of 401(k) and IRA accounts, Use, Financial adviser, Schwab, Privacy

TD Ameritrade is enhancing its award-winningi thinkorswim trading product suite with a host of new features and services as the integration with Schwab continues to move forward.

Key Points: 
  • TD Ameritrade is enhancing its award-winningi thinkorswim trading product suite with a host of new features and services as the integration with Schwab continues to move forward.
  • Additionally, in an early example of how TD Ameritrade trader clients will benefit from the integration and the breadth and depth of what the combined firm will offer, TD Ameritrade launched a virtual Active Trader Branch in April.
  • As with the Schwab service, traders must meet a set of requirements to work with the TD Ameritrade Active Trader Branch, but as always, all TD Ameritrade clients continue to have access to live 24/7 service and support.
  • TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank.

Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government

Retrieved on: 
Vendredi, juin 10, 2022
Bavarian Nordic, Janssen Pharmaceuticals, Goal, Smallpox, Company, Research, HHS, Johnson & Johnson, United States Department of Health and Human Services, EBITDA, Monkeypox, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Smallpox vaccine, Tick-borne encephalitis, Contract, RSV, Forward-looking statement, CEO, Office of Inspector General, U.S. Department of Health and Human Services, Government, U.S. Department of Defense Strategy for Operating in Cyberspace, Investment, Respiratory syncytial virus, Vaccinia, Vaccine, FDA, Development, Rabies, Assistant, BARDA, COVID-19, Immune system, Department, Futures contract, OMX, USD, DKK, Pharmaceutical industry

The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.

Key Points: 
  • The doses will be manufactured from bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic.
  • The majority of this bulk, however, will be converted to approximately 13 million freeze-dried doses of JYNNEOS during 2023-2025.
  • We are pleased to support BARDA in their continued efforts to build and strengthen the national preparedness against smallpox and monkeypox.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

Grupo Supervielle Reports 1Q22 Results

Retrieved on: 
Lundi, mai 16, 2022
Banking, Other Professional Services, Professional Services, Finance, Mach, Income, Company, Bank account, IMF, Ares Management, Environment, CB Bank, Bank, Investment, Common equity, GDP, Â, Coverage, LLP, Weather, Central bank, Chief executive officer, Quarter, Futures contract, IFRS, NPL, Yoy, Acquisition, NIM, BYMA, NYSE, CEO, Financial adviser, Music, Online gambling, Jules Supervielle

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company), a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three-month period ended March 31, 2022.

Key Points: 
  • Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company), a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three-month period ended March 31, 2022.
  • Commenting on first quarter 2022 results, Patricio Supervielle, Grupo Supervielle's Chairman & CEO, noted:
    We delivered a 90 basis point sequential increase in net interest margin during the first quarter, reflecting mainly higher yields for both our loan book and Central Bank securities held in our investment portfolio.
  • At IUD, results were affected by higher inflation and loan loss provisions coupled with a deep reduction in personnel.
  • Excluding non-recurring severance charges, Supervielle would have delivered net income of AR$445.6 million in 1Q22, with adjusted ROAE in real terms at approximately 2.9%, compared to 0% in previous quarter.

Univar Solutions Joins Collaborative Scholarship Initiative to Enhance Equity, Diversity and Inclusion in Chemical and Ingredient Industry

Retrieved on: 
Mardi, avril 5, 2022
Futures contract, Company, ACC, Organization, American Institute, American Institute of Chemical Engineers, Mentorship, STEM, Forward-looking statement, Transport, Multimedia, Parent, NYSE, Chemical industry, Living Together, Growing Together, Historically black colleges and universities, Univar Solutions, Accident, Health, U.S. Securities and Exchange Commission, Workforce, American, Learning, View, Security (finance), Industry, Technology, Securities Exchange Act of 1934, Securities Act of 1933, American Chemistry Council, COVID-19, Student, Science, Energy Independence and Security Act of 2007, Solution, Terminology, Education, OXO-biodegradation, Engineering, Future, Management, Risk management, University

DOWNERS GROVE, Ill., April 5, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a global chemical and ingredient distributor and provider of value-added services, today announced its engagement in the Future of STEM Scholars Initiative (FOSSI), the chemical industry's collaborative equity, diversity, and inclusion initiative aimed at creating pathways for more underrepresented groups to enter and succeed in science, technology, engineering and math (STEM) careers in the chemical industry.

Key Points: 
  • FOSSI creates lasting and meaningful relationships between students and sponsors, helping to create a diverse pipeline of future workforce talent.
  • FOSSI has an ambitious goal of supporting 1000 scholars through 2025, at an investment of nearly $50 million dollars.
  • "FOSSI brings together the industry's collective might to make a significant impact on the future of the chemical industry.
  • Univar Solutions (NYSE: UNVR) is a leading global commodity and specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers.

Univar Solutions Joins Collaborative Scholarship Initiative to Enhance Equity, Diversity and Inclusion in Chemical and Ingredient Industry

Retrieved on: 
Mardi, avril 5, 2022
Futures contract, Company, ACC, Organization, American Institute, American Institute of Chemical Engineers, Mentorship, STEM, Forward-looking statement, Transport, Parent, NYSE, Chemical industry, Living Together, Growing Together, Historically black colleges and universities, Univar Solutions, Accident, Health, U.S. Securities and Exchange Commission, Workforce, American, Learning, Security (finance), Industry, Technology, Securities Exchange Act of 1934, Securities Act of 1933, American Chemistry Council, COVID-19, Student, Science, Energy Independence and Security Act of 2007, Solution, Terminology, Education, OXO-biodegradation, Engineering, Future, Management, Risk management, University

DOWNERS GROVE, Ill., April 5, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a global chemical and ingredient distributor and provider of value-added services, today announced its engagement in the Future of STEM Scholars Initiative (FOSSI), the chemical industry's collaborative equity, diversity, and inclusion initiative aimed at creating pathways for more underrepresented groups to enter and succeed in science, technology, engineering and math (STEM) careers in the chemical industry.

Key Points: 
  • FOSSI creates lasting and meaningful relationships between students and sponsors, helping to create a diverse pipeline of future workforce talent.
  • FOSSI has an ambitious goal of supporting 1000 scholars through 2025, at an investment of nearly $50 million dollars.
  • "FOSSI brings together the industry's collective might to make a significant impact on the future of the chemical industry.
  • Univar Solutions (NYSE: UNVR) is a leading global commodity and specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers.

Grupo Supervielle Reports 4Q21 Results

Retrieved on: 
Mercredi, mars 2, 2022
Banking, Other Professional Services, Professional Services, Finance, Quarter, Risk, Sustainability accounting, Central bank, Kavak, Risk-weighted asset, Investment, Policy, Industry, Comprehensive income, Global, Chief executive officer, Income, Capital requirement, Traction, Global Reporting Initiative, Asset, Accumulated other comprehensive income, BYMA, NYSE, Common equity, CB Bank, Sale, Company, IFRS, ESG, FX, Communication, Efficiency, Acquisition, Private sector, ROE, Time from NPL (MSF), Tax, CEO, Jules Supervielle, NPL, NIM, LLP, Bank, Sustainability Accounting Standards Board, Disclosure, Retirement, Sustainability reporting, Acceleration, City, Yoy, Futures contract, Coverage, Retail, Cryptocurrency, Aquaculture, Music

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three- and twelve-month periods ended December 31, 2021.

Key Points: 
  • Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (Supervielle or the Company) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three- and twelve-month periods ended December 31, 2021.
  • Starting 1Q20, the Company began reporting results applying Hyperinflation Accounting, in accordance with IFRS rule IAS 29 (IAS 29) as established by the Central Bank.
  • This report also includes Managerial figures which exclude the IAS29 adjustment for 4Q21, 3Q21, 2Q21, 1Q21 and 4Q20
    Commenting on fourth quarter 2021 results, Patricio Supervielle, Grupo Supervielle's Chairman & CEO, noted:
    During 2021 we made significant strides across the Company toward achieving our strategic goals.
  • Loan loss provisions, net, which includes reversed provisions, amounted to AR$1.3 billion in 4Q21 compared to AR$1.3 billion in 3Q21, flat QoQ.

T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

Retrieved on: 
Mardi, janvier 11, 2022
Sepsis, Patient, Office of the Assistant Secretary for Preparedness and Response, Clinical trial, Private Securities Litigation Reform Act, SEC, Office of Inspector General, U.S. Department of Health and Human Services, Regulation of tobacco by the U.S. Food and Drug Administration, Adoption, Risk, NASDAQ, Marker beacon, CEO, Biomedical Advanced Research and Development Authority, GLOBE, Assistant, BARDA, Health, Development, Public health, Futures contract, Global health, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Time, U.S. Securities and Exchange Commission, Culture, Company, CE, BioSystems, Contract, Food, Blood culture, FDA, Hospital, Failure, Fungus, Annual report, Pharmaceutical industry, Vaccine

The Company plans to file the FDA submission for the T2Resistance Panel in 2022 following completion of the clinical trial, which will include up to 1,500 patients across 10 U.S. hospitals.

Key Points: 
  • The Company plans to file the FDA submission for the T2Resistance Panel in 2022 following completion of the clinical trial, which will include up to 1,500 patients across 10 U.S. hospitals.
  • The trial is estimated to cost T2 Biosystems $2,500,000.
  • We are pleased to have initiated the U.S. clinical trial for the T2Resistance Panel ahead of schedule, which should provide a path to file the FDA submission during 2022, said John Sperzel, Chairman and CEO at T2 Biosystems.
  • T2 Biosystems products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology.

T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

Retrieved on: 
Mardi, janvier 11, 2022
Face, Patient, Technology, Office of the Assistant Secretary for Preparedness and Response, Government, Clinical trial, Private Securities Litigation Reform Act, SEC, Office of Inspector General, U.S. Department of Health and Human Services, Regulation of tobacco by the U.S. Food and Drug Administration, Adoption, Risk, NASDAQ, CEO, Panel, Biomedical Advanced Research and Development Authority, GLOBE, Assistant, BARDA, Health, Development, Futures contract, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, U.S. Securities and Exchange Commission, Company, Biosafety, Instrument, BioSystems, Contract, Food, Blood culture, Unitary state, FDA, Failure, Annual report, Pharmaceutical industry, Vaccine, Medical imaging

The T2Biothreat Panel, which runs on T2 Biosystems T2Dx Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracis, F. tularensis, Burkholderia spp., Y. pestis,and R. prowazekii.

Key Points: 
  • The T2Biothreat Panel, which runs on T2 Biosystems T2Dx Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracis, F. tularensis, Burkholderia spp., Y. pestis,and R. prowazekii.
  • We are pleased to initiate the clinical trial for our novel T2Biothreat Panel as we continue to advance our product development strategy ahead of schedule, said John Sperzel, Chairman and CEO at T2 Biosystems.
  • T2 Biosystems products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology.
  • T2 Biosystems has an active pipeline of future products, including the T2Cauris Panel, and T2Lyme Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.